-+ 0.00%
-+ 0.00%
-+ 0.00%

Guangzhou Innogen Subsidiary Licenses Efsubaglutide Alfa to Arcera in Deal Potentially Worth Over US$ 1 Billion

PUBT·11/19/2026 09:10:05
Listen to the news
Guangzhou Innogen Subsidiary Licenses Efsubaglutide Alfa to Arcera in Deal Potentially Worth Over US$ 1 Billion
  • Guangzhou Innogen's indirect wholly owned subsidiary Hong Kong Innogen signed an Efsubaglutide Alfa licensing agreement with Arcera on November 19, 2026.
  • The exclusive license covers regulatory development and commercialization in selected emerging markets for an initial 15-year term.
  • Hong Kong Innogen is entitled to upfront and near-term milestone payments totaling up to US$ 38 million, including US$ 15 million nonrefundable upfront.
  • Additional payments include sales milestones and tiered royalties reaching double-digit rates on aggregate annual net sales in the licensed territory.
  • The deal's total potential value exceeds US$ 1 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261119-12418410), on November 19, 2026, and is solely responsible for the information contained therein.